University of Southern California

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Southern California sits in the top decile of US sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count).

617 total trials 97 currently recruiting 361 completed early-phase tilt top decile by trial count

University of Southern California: 617 sponsored US clinical trials, 97 recruiting.

University of Southern California sponsors 617 registered US clinical trials on ClinicalTrials.gov, 97 of them currently recruiting, and 361 completed. 31 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.

Top-decile sponsor footprint

University of Southern California ranks in the top decile of sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 33/100

361 of 466 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

617 total, page 9 of 13

TERMINATED

Bone, Endocrine and Lifestyle Longitudinal Study

NCT02063074

COMPLETED NA

Study of Mobile Phone Delivered Intervention to Reduce Alcohol Consumption

NCT02158949

COMPLETED

Reducing the Duration of Untreated Psychosis

NCT03102151

COMPLETED NA

Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth

NCT02088294

COMPLETED NA

Project Bridge: Peer Health Navigator Intervention

NCT02022462

COMPLETED

Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer

NCT02370290

COMPLETED NA

Triggers and Responses to Simulator Sickness in Videogame Players

NCT02122354

COMPLETED NA

Nattokinase Atherothrombotic Prevention Study

NCT02080520

TERMINATED NA

Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy

NCT02122341

COMPLETED Phase 1

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

NCT02091921

COMPLETED

Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers

NCT03563651

TERMINATED NA

18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

NCT02079181

COMPLETED Phase 2

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909

TERMINATED NA

Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers

NCT02057991

TERMINATED Phase 1

Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery

NCT02067884

COMPLETED NA

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466

TERMINATED NA

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

NCT01712815

COMPLETED Phase 1

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

NCT01957995

TERMINATED Phase 2

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01866423

COMPLETED NA

A Helping Hand Among Low-Income Patients

NCT02147522

COMPLETED NA

Harnessing mHealth and Social Support to Improve Diabetes Related Health Behavior for Inner-city Patients

NCT01945996

COMPLETED NA

Group Self-Management of Depression and Medical Illness

NCT02017262

TERMINATED Phase 2

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571

COMPLETED

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

NCT02225977

TERMINATED Phase 2

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

NCT01873833

COMPLETED NA

Resistance Training and Protein Supplementation for Prostate Cancer Survivors

NCT01909440

COMPLETED Phase 2

Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary

NCT01915069

COMPLETED

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755

COMPLETED NA

Beta Cell Restoration Through Fat Mitigation

NCT01763346

COMPLETED NA

Reducing PTSD in Hospitalized Burn Patients

NCT02026037

COMPLETED

Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill

NCT02104609

COMPLETED NA

Moderate Versus Aggressive Fluids for Acute Pancreatitis

NCT01761539

TERMINATED Phase 1

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

NCT01801046

COMPLETED NA

Safety and Effectiveness Study: Role Playing Game for Friends and Family of Service Members

NCT01807806

COMPLETED Phase 1

Multi-cycle Prolon Diet

NCT02158897

COMPLETED NA

Laser Versus Mechanical Lithotripsy of Bile Duct Stones

NCT01759979

TERMINATED NA

Light-Scattering Spectroscopy for Detection of Breast Cancer

NCT01755208

TERMINATED NA

Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer

NCT02370264

COMPLETED

A Study of Brain Aging in Vietnam War Veterans

NCT01687153

TERMINATED Phase 1

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

NCT01642342

TERMINATED Phase 1

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

NCT01649258

COMPLETED Phase 2

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

NCT01676818

COMPLETED NA

Text Message Appointment Reminders

NCT01676337

COMPLETED NA

Phytoserms for Menopause Symptoms and Age-Associated Memory Decline

NCT01723917

COMPLETED NA

Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis

NCT01758549

TERMINATED Phase 2

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

NCT01469338

COMPLETED

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

NCT01592097

COMPLETED NA

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

NCT01667978

COMPLETED NA

Exercise Program for Early Breast Cancer Survivors

NCT01140282

COMPLETED

Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

NCT03107689

← Previous Page 9 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 83
Phase 2 90
Phase 3 9
Phase 4 22

What is open in the University of Southern California pipeline

97 recruiting of 617 indexed (16% open); 361 completed (59%).

Phase mix: 31 late (III/IV) vs 173 early (I/II) (early-phase heavy).

Top condition: Obesity (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Southern California: open-pipeline peers nationwide

Peers matched on 617 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share University of Southern CaliforniaBaylor College of MedicineUS Department of Veterans AffairsUniversity of RochesterJanssen Research & DevelopmentYoungstown State UniversityRoswell Park Cancer InstituteFox Chase Cancer CenterUniversity of Oregon
University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 617 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of Southern California page

617 registered trials is a research-attention snapshot, not an endorsement of University of Southern California or any single study.

  • 97 of University of Southern California's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Southern California studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Southern California pipeline card: 617 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.